Psoriatic arthritis (PsA) is a chronic inflammatory disease where the immune system attacks the joints, tendons, and surrounding tissue, causing pain, swelling, and stiffness. It develops in roughly 20% of people who have psoriasis, with that number climbing to 25% in those with moderate to severe skin disease. What makes PsA visually distinct from other types of arthritis is the combination of swollen, discolored joints alongside skin plaques, characteristic nail changes, and a unique pattern of finger and toe swelling that doesn’t occur in other arthritic conditions.
How PsA Differs From Other Arthritis
PsA is often confused with rheumatoid arthritis (RA), but the two look and behave differently. RA tends to affect joints symmetrically, meaning both hands or both knees at the same time, and it favors the knuckles closest to the palm. PsA is more unpredictable. In its early stages, it often shows up as asymmetric inflammation, affecting one knee but not the other, or a few scattered fingers. It also has a strong preference for the small joints closest to the fingertips and toenails, a pattern rarely seen in RA.
Another distinguishing feature is what happens in the spine. PsA can inflame the sacroiliac joints (where the spine meets the pelvis) and the spinal ligaments, causing lower back stiffness that’s worse in the morning and improves with movement. RA almost never involves those areas. Blood tests help too: about 80% of RA patients test positive for rheumatoid factor, while nearly all PsA patients test negative. That said, roughly 13% of people with PsA do test positive, so a single lab result can’t rule the diagnosis in or out on its own.
Swollen “Sausage” Fingers and Toes
The most visually striking sign of PsA is dactylitis, commonly called “sausage digits.” Rather than swelling at a single knuckle, the entire finger or toe puffs up uniformly from base to tip, making it look like a small sausage. This happens because inflammation isn’t limited to the joint itself. It spreads through the tendons, tendon sheaths, and soft tissue running the full length of the digit.
Dactylitis occurs in 16 to 49% of people with PsA and is considered a hallmark of the disease. It can affect any finger or toe, and it doesn’t always hit both sides equally. You might have one swollen toe on the left foot and nothing on the right. When dactylitis is present, it’s one of the strongest clinical clues pointing toward PsA rather than RA or osteoarthritis, neither of which produces this pattern.
Nail Changes
Nail involvement is extremely common in PsA, affecting up to 80% of patients compared to about 40% of people with skin psoriasis alone. If you’re wondering whether joint pain might be connected to your psoriasis, your nails are one of the first places to look. Nail changes are a strong predictor of developing arthritis down the line.
The most common nail finding is pitting: tiny, pinpoint depressions scattered across the nail surface, as if someone pressed a ballpoint pen tip into the nail repeatedly. About 68% of psoriasis patients with nail disease have pitting. Other signs include:
- Oil drop spots: translucent yellow-red patches visible through the nail plate, sometimes called salmon patches. These are considered a telltale sign of psoriasis and don’t typically appear in other conditions.
- Onycholysis: the nail plate separating from the nail bed, starting at the tip and working backward. The detached area often looks white or yellowish.
- Subungual hyperkeratosis: a chalky, crumbly buildup of skin cells beneath the nail, which can thicken and lift the nail.
- Nail crumbling: in more advanced cases, the nail becomes rough, brittle, and may partially disintegrate.
These changes occur because the inflammatory process targets the nail matrix (where the nail grows) and the nail bed underneath. Nail psoriasis is uncommon in both RA and osteoarthritis, so its presence is a useful clue during diagnosis.
Enthesitis: Pain Where Tendons Meet Bone
Enthesitis is inflammation at the points where tendons and ligaments anchor into bone. It’s a core feature of PsA that doesn’t occur in RA, making it another distinguishing characteristic. The most commonly affected spots are the Achilles tendon at the back of the heel, the plantar fascia on the sole of the foot, and the areas around the knee and elbow where tendons attach.
Visually, enthesitis may cause localized swelling at the heel or the bottom of the foot, and the area is typically tender to the touch. Over time, chronic inflammation at these attachment points can trigger bony overgrowth, such as heel spurs. Many people with PsA first notice this as persistent heel pain that doesn’t respond to typical treatments for plantar fasciitis, which can delay the correct diagnosis.
What Drives the Inflammation
PsA is an autoimmune condition driven by an overactive immune response. The central problem is a signaling loop between two inflammatory molecules called IL-23 and IL-17. IL-23 activates a type of immune cell that then floods the joints, skin, and tendons with IL-17, triggering inflammation, tissue damage, and the recruitment of even more immune cells into the affected areas.
In the joints specifically, high levels of IL-17 and IL-23 accumulate in the synovial membranes (the tissue lining the joint capsule) and at the entheses. This sustained inflammation doesn’t just cause pain and swelling. It actively remodels bone, leading to both erosion (bone loss) and abnormal new bone formation at the margins of joints. This dual process of destruction and overgrowth is a distinguishing feature of PsA on X-rays and helps separate it from RA, which primarily causes erosion without significant new bone growth.
Joint Patterns You Might Notice
PsA doesn’t follow a single pattern. Rheumatologists have historically described five overlapping presentations, and many people shift between them over time. The most common early pattern is oligoarticular, meaning fewer than five joints are inflamed, often asymmetrically. You might have a swollen right index finger and a stiff left knee with nothing else visibly affected.
Some people develop a polyarticular pattern that looks more like RA, with many joints involved on both sides of the body. Others primarily experience spinal stiffness and sacroiliac pain. A smaller group develops predominant distal joint disease, where inflammation concentrates in the joints nearest the fingernails and toenails, causing those joints to become visibly red, swollen, and warm. In rare, severe cases, a destructive form called arthritis mutilans can shorten and telescope the fingers, though modern treatment has made this outcome uncommon.
How It’s Diagnosed
Doctors use a classification system called CASPAR to identify PsA. It requires evidence of inflammatory joint, spine, or tendon disease plus at least three points from the following criteria: current psoriasis (worth two points), a personal history of psoriasis, a family history of psoriasis, psoriatic nail changes, a negative rheumatoid factor test, current or past dactylitis, and X-ray evidence of new bone formation near joint margins. The system captures the full picture of the disease rather than relying on any single test.
There is no single blood test that confirms PsA. Diagnosis is clinical, meaning it depends on combining what the doctor sees on exam, your history, blood work to rule out RA, and imaging. Ultrasound and MRI can reveal inflammation in tendons and entheses that isn’t visible on the surface, which is especially useful in early disease when joint damage hasn’t appeared on standard X-rays yet.
Why Early Treatment Matters
PsA can cause permanent joint damage relatively quickly. In a study of patients with untreated early PsA, about 17% already had bone erosions visible on X-rays within the first eight months of symptoms. By two years, that number rose to roughly 24%. A diagnostic delay of more than two years from symptom onset is associated with faster damage progression, which is why rheumatologists push for early identification and treatment.
The first step in treatment for mild disease is typically a conventional disease-modifying drug that slows the immune response broadly. When that’s not enough, or when the disease is moderate to severe from the start, biologic medications that specifically block TNF-alpha, IL-17, or IL-23 are the mainstay of treatment. These target the exact inflammatory pathways driving the disease rather than suppressing the entire immune system. A newer class of oral medications called JAK inhibitors works by blocking the signaling inside immune cells and has shown sustained improvement across joint symptoms, skin disease, and physical function.
Current European guidelines generally reserve JAK inhibitors for people who haven’t responded to other treatments, while international GRAPPA guidelines allow more flexibility, considering them alongside biologics even earlier in the treatment course. The choice between these options depends on which aspects of the disease are most active, whether that’s joints, skin, enthesitis, or a combination.